Nuclera Raises $87M Series C To Advance Antibody Research

The extension round was led by Elevage Medical Technologies and Jonathan Milner with participation from existing investors including British Business Bank and GK Goh.

Nuclera develops eProtein Discovery, a benchtop platform that streamlines protein expression, purification and screening for drug discovery. By integrating cell-free systems, digital microfluidics and high-throughput data, it accelerates candidate identification, reduces costs, and improves efficiency. Upcoming antibody-specific capabilities will support end-to-end workflows and AI-driven biologics research.

Read Also - UK’s Verna Raises $4M To Drive Biodiversity Restoration

According to CEO and co-founder Dr. Michael Chen the funding underscores Nuclera’s growing momentum and its strategy to establish eProtein Discovery as a leading platform in the rapidly expanding biologics R&D sector.

Scientists increasingly require scalable, high-quality datasets to power AI models in biologics discovery. They are positioning Nuclera to become a foundational platform for the future of protein and antibody engineering ultimately accelerating therapeutic discovery timelines.

The funding will accelerate the addition of antibody expression and binding validation features to the eProtein Discovery system enabling comprehensive in-house protein screening, characterisation and high-throughput expression.

About Nuclera

Founded in 2013 Nuclera pioneers multiplex protein screening with its eProtein Discovery™ platform, bringing rapid, reliable protein access to the benchtop. The company removes uncertainty from protein science, helping researchers accelerate discoveries, focus on innovation, and make breakthroughs in human health while making protein access routine for every lab.